Targeting the ERBB family in cancer: couples therapy
N Tebbutt, MW Pedersen, TG Johns - Nature Reviews Cancer, 2013 - nature.com
The ERBB family of receptor tyrosine kinases has a central role in the tumorigenesis of many
types of solid tumour. Various therapeutics targeting these receptors have been approved …
types of solid tumour. Various therapeutics targeting these receptors have been approved …
Impact of EGFR inhibitor in non–small cell lung cancer on progression-free and overall survival: a meta-analysis
Background The epidermal growth factor receptor (EGFR) signaling pathway is crucial for
regulating tumorigenesis and cell survival and may be important in the development and …
regulating tumorigenesis and cell survival and may be important in the development and …
Planning cancer control in Latin America and the Caribbean
PE Goss, BL Lee, T Badovinac-Crnjevic… - The lancet …, 2013 - thelancet.com
Non-communicable diseases, including cancer, are overtaking infectious disease as the
leading health-care threat in middle-income and low-income countries. Latin American and …
leading health-care threat in middle-income and low-income countries. Latin American and …
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus …
Purpose We examined the impact of different epidermal growth factor receptor (EGFR)
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance
A Levitzki - Annual review of pharmacology and toxicology, 2013 - annualreviews.org
With the manufacture of imatinib, researchers introduced tyrosine kinase inhibitors (TKIs)
into the clinical setting in 2000 to treat cancers; approximately fifteen other TKIs soon …
into the clinical setting in 2000 to treat cancers; approximately fifteen other TKIs soon …
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
HY Tu, EE Ke, JJ Yang, YL Sun, HH Yan, MY Zheng… - Lung Cancer, 2017 - Elsevier
Introduction Patients with non-small cell lung cancer (NSCLC) harboring uncommon
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …
[HTML][HTML] ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma
M Ilie, E Long, C Butori, V Hofman, C Coelle, V Mauro… - Annals of oncology, 2012 - Elsevier
Background A subgroup of anaplastic lymphoma kinase (ALK)-rearranged lung tumours can
respond to ALK inhibitors. Until now, the ALK status in circulating tumour cells (CTCs) …
respond to ALK inhibitors. Until now, the ALK status in circulating tumour cells (CTCs) …
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer: a meta-analysis of 13 randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical lung cancer, 2012 - Elsevier
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: a …
G Gao, S Ren, A Li, J Xu, Q Xu, C Su… - … journal of cancer, 2012 - Wiley Online Library
Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …
Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non–small-cell lung cancer
SM Gadgeel, A Wozniak - Clinical lung cancer, 2013 - Elsevier
Mutations in the epidermal growth factor receptor gene (EGFR) are frequently observed in
non–small-cell lung cancer (NSCLC), occurring in about 40% to 60% of never-smokers and …
non–small-cell lung cancer (NSCLC), occurring in about 40% to 60% of never-smokers and …